Department of Otolaryngology-Head & Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, North 15 West 7, Sapporo 060-8638, Japan.
Department of Otolaryngology-Head & Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, North 15 West 7, Sapporo 060-8638, Japan.
Auris Nasus Larynx. 2021 Feb;48(1):41-49. doi: 10.1016/j.anl.2020.11.018. Epub 2020 Dec 4.
Endonasal endoscopic surgery (EES) has been applied to the management of sinonasal (SN) tumors based on recent advances in endoscopic surgical techniques and technologies over the past three decades. EES has been mainly indicated for benign tumors and less aggressive malignant tumors. Notwithstanding this, EES has been gradually adopted for squamous cell carcinoma (SCC), which is the most common histology among SN malignancies. However, an analysis of the outcomes of EES for patients with SCC is difficult because most articles included SCC a wide range of different tumor histologies. Therefore, we herein review and clarify the current status of EES focusing on SCC from an oncological perspective. The oncologic outcomes and the ability to achieve a histologically complete resection are similar between endoscopic and open approaches in highly selected patients with SN-SCC. Surgical complications associated with EES are likely similar for SN-SCC compared to other sinonasal malignancies. The indications for a minimally invasive approach such as EES in the management of patients with SN-SCC should be stricter than those for less aggressive malignant tumors because of the aggressive nature of SCC. Also, it is important to achieve negative surgical margins with EES in patients with SCC. We believe that the indications for EES for SN-SCC are widening due to advances in diagnostic imaging, and endoscopic surgical techniques and technologies. However, while expanding the indications for EES for SN-SCC we must carefully confirm that the outcomes support this strategy.
经鼻腔内镜手术(EES)基于过去三十年中内镜手术技术和技术的最新进展,已应用于治疗鼻腔鼻窦(SN)肿瘤。EES 主要适用于良性肿瘤和侵袭性较低的恶性肿瘤。尽管如此,EES 已逐渐用于鳞状细胞癌(SCC),这是 SN 恶性肿瘤中最常见的组织学类型。然而,由于大多数文章都将 SCC 纳入了广泛的不同肿瘤组织学类型,因此分析 EES 治疗 SCC 患者的结果具有一定难度。因此,我们从肿瘤学的角度回顾和阐明了 EES 治疗 SCC 的现状。在高度选择的 SN-SCC 患者中,EES 和开放式手术的肿瘤学结果和实现组织学完全切除的能力相似。与其他鼻窦恶性肿瘤相比,EES 相关的手术并发症可能在 SN-SCC 中相似。由于 SCC 的侵袭性,EES 等微创方法治疗 SN-SCC 的适应证应比侵袭性较低的恶性肿瘤更严格。此外,EES 治疗 SCC 患者时,实现阴性手术切缘很重要。我们相信,由于诊断成像、内镜手术技术和技术的进步,EES 治疗 SN-SCC 的适应证正在扩大。然而,在扩大 EES 治疗 SN-SCC 的适应证时,我们必须仔细确认该策略的结果是否支持这一策略。